The Body First Trial Protocol™
- May 19
- 26 min read
Rethinking Medication Introduction for in MCAS, Long COVID, and Infection Associated Chronic Conditions
By Cynthia Adinig
Executive Summary
Patients with mast cell activation syndrome (MCAS), Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), postural orthostatic tachycardia syndrome (POTS), dysautonomia, and multiple chemical sensitivity (MCS) frequently report disproportionate or unpredictable reactions to medications, supplements, foods, beverages, fragrances, fillers, dyes, preservatives, and environmental exposures. These reactions are often dismissed as anxiety, medication avoidance, somatization, or nonspecific intolerance despite increasing evidence that these populations may exhibit altered physiologic thresholds involving mast cell signaling, autonomic regulation, vascular compensation, neuroinflammation, and impaired adaptive reserve (Afrin, 2016; Valent et al., 2012; Sumantri and Rengganis, 2023).
Conventional medication initiation protocols assume relatively stable dose response relationships and predictable reaction timing. In highly reactive neuroimmune populations, however, tolerability may be influenced not only by the active compound itself, but also by exposure speed, dose concentration, excipient burden, hormonal state, inflammatory load, environmental conditions, autonomic instability, and recent physiologic stressors. As a result, some patients who fail standard titration protocols may still tolerate the same intervention when introduced through slower, lower concentration, or state-aware exposure sequencing.
The Body First Trial Protocol™ was developed as a conservative sequential exposure framework for patients with complex immunologic and autonomic sensitivity. The protocol prioritizes physiologic signaling over conventional dosing timelines by gradually progressing from external exposure to mucosal exposure and finally to diluted systemic administration. This approach is intended to reduce destabilization risk while preserving access to potentially beneficial therapies that might otherwise be abandoned. Within this framework, medication intolerance is interpreted not as binary incompatibility, but as a mismatch between exposure burden and current physiologic buffering capacity. From this perspective, failed tolerance may reflect autonomic instability, inflammatory amplification, excipient sensitivity, impaired adaptive reserve, or exposure timing rather than true pharmacologic incompatibility alone.
What Is The Body-First Trial Protocol™?
Patients with mast cell activation syndrome (MCAS), Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), postural orthostatic tachycardia syndrome (POTS), dysautonomia, and multiple chemical sensitivity (MCS) frequently report disproportionate or unpredictable reactions to medications, supplements, foods, beverages, fragrances, fillers, preservatives, and environmental exposures. These reactions are often dismissed as anxiety, medication avoidance, somatization, or nonspecific intolerance despite increasing evidence that these populations may exhibit altered physiologic thresholds involving mast cell signaling, autonomic regulation, vascular compensation, neuroinflammation, and impaired adaptive reserve (Afrin, 2016; Valent et al., 2012; Sumantri and Rengganis, 2023).
Conventional medication initiation protocols assume relatively stable dose response relationships and predictable reaction timing. In highly reactive neuroimmune populations, however, tolerability may be influenced not only by the active compound itself, but also by exposure speed, dose concentration, excipient burden, hormonal state, inflammatory load, environmental conditions, autonomic instability, and recent physiologic stressors. As a result, some patients who fail standard titration protocols may still tolerate the same intervention when introduced through slower, lower concentration, or state-aware exposure sequencing.
This state-dependence of reactivity is routinely underrecognized in standard clinical frameworks. Clinical care pathways assume a relatively stable baseline physiology. Medication guidelines assume that patients can introduce interventions incrementally and assess side effects in a linear fashion. Patients who cannot do so are frequently labeled “too sensitive,” “too complex,” anxious, or noncompliant, and are often excluded from further therapeutic escalation or research participation (FDA, 2023; NIH RECOVER, 2024).
The Body First Trial Protocol™ builds directly on CYNAERA’s STAIR Stable Method™ framework. First introduced in CYNAERA’s white paper The Science of Remission: Reversing the Terrain of Infection Associated Chronic Conditions, STAIR stands for Stabilization, Tolerance, and Immune Readiness. STAIR was developed as a biologic preparation framework intended to reduce destabilization risk before introducing medications, supplements, foods, procedures, rehabilitation stressors, or clinical trial interventions.
Within the STAIR framework, treatment readiness is not determined solely by diagnosis or treatment indication. Instead, readiness is interpreted through terrain stability across immune, autonomic, hormonal, inflammatory, and neurovascular systems. This approach recognizes that many adverse reactions may not represent true substance incompatibility, but rather state-dependent physiologic overload occurring in biologically unstable systems.
The Body First Trial Protocol™ operationalizes this principle through sequential exposure architecture. Rather than assuming immediate systemic exposure is safe, the protocol gradually progresses from external contact exposure to mucosal exposure and finally to diluted systemic administration. This barrier to systemic sequencing strategy is intended to preserve therapeutic access while minimizing destabilization risk in highly reactive populations.
Intended Use
This protocol is intended for patients with documented or suspected mast cell activation, autonomic instability, post-viral syndromes, neuroimmune hypersensitivity, or multiple chemical sensitivity who have experienced difficulty tolerating standard medication initiation protocols.
Applicable populations include, but are not limited to, mast cell activation syndrome (MCAS), Long COVID, ME/CFS, POTS, Lyme, dysautonomia, multiple chemical sensitivity, connective tissue disorders with mast cell features, autoimmune, and other chronic inflammatory or post-infectious neuroimmune syndromes. This protocol does not replace allergy evaluation, emergency medical care, physician directed treatment planning, or standard anaphylaxis management. Instead, it is intended as a conservative exposure framework for complex patients who repeatedly fail conventional initiation strategies despite clinical need.
Super Sensitive Screening Criteria: MCAS Flag™ Triage Tool
The MCAS Flag™ Triage Tool is a preliminary screening framework designed to identify patients who may have undiagnosed, underrecognized, or clinically relevant mast cell activation patterns, particularly when standard allergy panels, IgE testing, or routine laboratory findings are inconclusive. The tool is intended for use in Long COVID, ME/CFS, POTS, dysautonomia, multiple chemical sensitivity, and other infection associated chronic condition populations where hypersensitivity, medication intolerance, environmental reactivity, and autonomic instability frequently overlap (Afrin, 2016; Valent et al., 2012; Doherty et al., 2018; Sumantri and Rengganis, 2023).
Patients may be flagged for mast cell informed evaluation when three or more of the following criteria are present: low dose medication or supplement sensitivity; long-standing personal history of food, dust, pollen, medication, or environmental allergies; family clustering of asthma, eczema, seasonal allergies, unexplained anaphylaxis, or medication intolerance; new or worsening allergies, food intolerance, rashes, or chemical sensitivity after COVID or another infection; comorbid POTS, ME/CFS, Long COVID, PEM, orthostatic intolerance, or unexplained fatigue; flares triggered by perfumes, smoke, cleaning products, new furniture, off gassing, mold, or other environmental exposures; and gastrointestinal reactivity including IBS-like symptoms, nausea, bloating, diarrhea, or food triggered symptom worsening.
A score of zero to two points suggests lower likelihood of clinically significant mast cell involvement, though future changes should still be monitored if symptoms evolve.
A score of three to four points suggests possible mast cell involvement and may justify further clinical evaluation, environmental trigger assessment, and cautious consideration of H1/H2 blockade or mast cell directed strategies under clinician guidance.
A score of five to seven points suggests a high likelihood mast cell sensitive phenotype and supports use of conservative exposure sequencing, medication formulation review, environmental remediation assessment, and discussion of mast cell stabilizers, dietary adjustments, or rescue planning with an appropriate clinician.
A major red flag is the patient who reports reacting to “nearly everything” or describes themselves as someone who “always has weird reactions.” Within this framework, that language should not be dismissed as anxiety, exaggeration, or noncompliance. Instead, it should trigger mast cell informed evaluation, review of excipient sensitivity, autonomic assessment, and use of the Body First Trial Protocol™ before initiating new medications, supplements, foods, or beverages.
Environmental Trigger Check: N95 Air Test™
The N95 Air Test™ is designed to help determine whether airborne environmental triggers are contributing to persistent flares, symptom plateau, heightened reactivity, or poor tolerance of new interventions. In highly reactive MCAS, Long COVID, ME/CFS, POTS, dysautonomia, and MCS populations, inhaled exposures may meaningfully contribute to symptom amplification even when the patient is primarily focused on food, medication, or supplement intolerance. Mold, wildfire particulates, volatile organic compounds, cleaning products, fragrances, smoke, off-gassing furniture, and indoor air quality shifts may all function as ongoing physiologic stressors in chemically sensitive or mast cell-reactive patients.
Protocol
Wear a well-fitted N95 respirator, or layered masking if an N95 is not available, continuously during waking hours for 12 to 24 hours, ideally extending over a two day observation period.
Maintain baseline diet, supplements, medications, hydration, activity level, and environmental routine during the test period. Do not introduce new supplements, medications, foods, cleaning products, air purifiers, or major environmental changes during the testing window. The purpose is to isolate whether reduced airborne exposure changes symptoms.
If tolerated, patients with suspected nighttime symptom spikes may include overnight sleep with the mask during the observation period. This may be especially relevant when symptoms include increased nighttime tachycardia, insomnia, waking short of breath, morning headache, early morning air hunger, overnight flushing, or worsening upon waking.
Patients should not sleep in a mask if it causes breathing discomfort, panic, distress, skin breakdown, unsafe sleep disruption, or any sense of respiratory limitation.
Expected Response
Improvement by the end of Day 2 may suggest that ongoing airborne exposure is contributing to symptom burden.
Relevant improvements may include reduced brain fog, less flushing, fewer palpitations, improved sleep, lower morning reactivity, reduced headache, decreased throat irritation, improved breathing comfort, or improved tolerance of baseline foods or medications.
No significant improvement does not rule out environmental contribution. Some patients may require a longer observation period before their inflammatory, autonomic, or mast cell systems show meaningful improvement. In other cases, masking may reduce inhaled exposure but not fully protect against airborne irritants reaching the eyes, skin, hair, clothing, bedding, or surrounding surfaces. This is especially relevant for mold fragments, volatile organic compounds, fragrances, cleaning residues, wildfire particulates, and other persistent indoor exposures.
If symptoms do not improve during the N95 Air Test™ but environmental exposure remains strongly suspected, a more complete environmental separation trial may be needed. This may involve spending 48 to 72 hours in a different low-exposure space outside the home, such as a trusted friend’s home, hotel, or other cleaner environment, while avoiding new foods, supplements, medications, or major routine changes. Improvement away from the original environment, especially if followed by worsening upon return, may provide a stronger signal that the home, workplace, or indoor environment is contributing to symptom persistence.
Why It Works
Many highly reactive patients are unaware that inhaled exposures, rather than ingested substances alone, may be sustaining their flare state. In this context, masking functions as a temporary exposure reduction tool that may reveal whether the body improves when airborne triggers are partially filtered. This is especially relevant for hidden mold exposure, wildfire smoke, cleaning product sensitivity, fragrance exposure, volatile organic compounds, off gassing furniture, and particulate reactivity in Long COVID and MCAS sensitive patients.
Clinical Caution
This test is not a diagnostic substitute for professional mold assessment, indoor air quality evaluation, allergy testing, occupational exposure review, or medical evaluation. It should be understood as a crude but potentially useful biologic air-filter challenge.
Advanced Add-On: Temporary Relocation Test
For patients who experience notable improvement during the N95 Air Test™, a short environmental relocation trial may be considered when feasible and safe.
This may involve spending 48 to 72 hours in a lower-exposure setting, such as a trusted friend’s home, hotel, outdoor-oriented environment, or another location with fewer suspected triggers.
During this period, patients should avoid introducing new medications, foods, supplements, or major interventions so that symptom changes can be more clearly attributed to the environmental shift. Improvement outside the original environment, followed by worsening upon return, may support further investigation of mold, VOCs, particulate exposure, fragrance burden, or other indoor air quality concerns.
When to Use This Step
This environmental isolation step should occur before new substance trials when a patient has a high MCAS Flag™ score, persistent unexplained flares, poor tolerance of multiple interventions, or symptom patterns that worsen in specific rooms, buildings, weather conditions, wildfire smoke periods, mold-prone spaces, or chemically treated environments.
Why Physiologic Stability Matters Before Escalation
The Body First Trial Protocol™ should not be initiated during periods of significant physiologic instability, as inflammatory amplification, autonomic dysregulation, mast cell activation, hormonal fluctuation, infection, environmental exposure, and impaired adaptive reserve may substantially alter tolerability thresholds in highly reactive patients (Doherty et al., 2018; Wirth and Scheibenbogen, 2023; Rohrhofer et al., 2025). This stabilization first principle reflects the broader logic of CYNAERA’s STAIR Stable Method™, which prioritizes immune, autonomic, and inflammatory stabilization before introducing new physiologic stressors, therapeutic exposures, supplements, foods, or clinical trial interventions.
Accordingly, the protocol should not be initiated under the following conditions:
• Active flare state
• Recent anaphylaxis or near-syncope
• Acute infection or suspected viral reactivation
• Recent major environmental exposure, including mold or wildfire smoke
• Significant psychosocial or physiologic stressor
• Perimenstrual windows in patients with known hormone linked reactivity
These recommendations reflect increasing recognition that physiologic state may significantly influence mast cell responsiveness, autonomic compensation, inflammatory amplification, and symptom severity in MCAS, Long COVID, ME/CFS, dysautonomia, and related neuroimmune conditions (Sumantri and Rengganis, 2023; El-Rhermoul et al., 2023).
Prior to initiation, clinicians are encouraged to review prior adverse drug reactions, establish baseline blood pressure and heart rate when clinically appropriate, pre-authorize emergency medication escalation plans, and ensure that patients have access to rescue medications and emergency support if needed. These precautions are particularly important in populations with prior histories of severe medication intolerance, autonomic collapse, mast cell mediated reactions, or delayed post-exertional physiologic worsening (Shaker et al., 2020; Golden et al., 2024).
Sequential Exposure Framework
The Body First Trial Protocol™ utilizes a sequential barrier-to-systemic exposure model designed to minimize destabilization risk while preserving therapeutic access in highly reactive patients. Rather than introducing full systemic exposure immediately, the protocol gradually progresses from external contact exposure to mucosal exposure and finally to diluted systemic administration. This approach reflects emerging evidence that concentration, exposure speed, excipient burden, autonomic state, inflammatory load, and environmental context may all influence tolerability in mast cell and neuroimmune populations (Caballero et al., 2021; Garvey et al., 2026).
Step 1: Cutaneous Contact Test (Day 1)
A minimal quantity of the substance is diluted and applied to intact skin, typically the volar forearm. Patients are observed over a 24-hour period for delayed local or systemic symptoms.
Monitored outcomes may include:
• Local erythema, pruritus, or flushing
• Fatigue, malaise, dizziness, or cognitive changes
• Tachycardia or autonomic symptoms
• Delayed inflammatory worsening
This initial step is intended to assess low-level external reactivity while minimizing systemic exposure burden. Although absence of reaction does not guarantee oral tolerance, the step may help identify obvious hypersensitivity patterns prior to progression.
Step 2: Repeated Cutaneous Exposure (Day 2)
Following gentle removal of residual material, the same diluted exposure is repeated to assess reproducibility or delayed sensitization effects. Patients are again monitored over a minimum 24-hour observation period.
Progression requires absence of clinically significant reaction.
The repeated exposure phase acknowledges that some mast cell and neuroimmune reactions may demonstrate delayed amplification patterns rather than immediate responses alone (Afrin, 2016; Theoharides, Valent and Akin, 2015).
Step 3: Oral Mucosal Micro-Exposure (Day 3)
A highly diluted oral solution is prepared, and the patient applies only a minimal volume to the oral mucosa without swallowing. This step assesses mucosal tolerance while limiting full gastrointestinal absorption and systemic exposure.
Observation period: minimum 24 hours.
This stage is particularly important for highly reactive patients with histories of severe gastrointestinal activation, autonomic instability, or rapid systemic escalation following oral exposures. The protocol recognizes that mast cell and neuroimmune populations may react not only to active compounds themselves, but also to concentration kinetics, absorption speed, and excipient burden (Reker et al., 2019; Caballero et al., 2021).
Step 4: Diluted Oral Micro-Dose (Day 4+)
If mucosal exposure is tolerated, a diluted oral dose equivalent to approximately one-tenth of the intended target dose is administered slowly over one to two hours rather than all at once.
Premedication with a previously tolerated H1 antihistamine may be considered at clinician discretion.
Observation period: minimum 24 hours.
This stage reflects the principle that exposure speed and concentration burden may influence tolerability independently of the substance itself. Some highly reactive patients appear capable of tolerating gradual low-concentration exposure despite failing conventional full-dose administration.
Step 5: Incremental Oral Dose Escalation (Day 6+)
Dose escalation proceeds gradually every 24 to 48 hours only if prior exposures are tolerated without clinically significant worsening.
Suggested progression:
1/8 dose → 1/4 dose → 1/2 dose → full dose
Escalation speed should be individualized according to reaction history, autonomic stability, inflammatory burden, and prior medication tolerance patterns.
The protocol intentionally prioritizes physiologic stability over speed of titration. This reflects increasing recognition that post-viral and mast cell-associated chronic illnesses often involve fluctuating adaptive reserve and delayed symptom amplification rather than static physiologic tolerance states (Komaroff and Lipkin, 2021; Wirth and Scheibenbogen, 2023).
Step 6: Standard Formulation Transition (Day 9+)
Once the target dose is tolerated in diluted form, transition to standard intact formulation begins with fractional dosing. Progression occurs conservatively and only with sustained tolerance.
This phase is important because some patients may tolerate the active compound in diluted form while reacting to formulation variables such as dyes, binders, capsule materials, preservatives, fillers, or altered absorption dynamics. Increasing literature suggests that excipient related hypersensitivity may contribute substantially to medication intolerance patterns in highly reactive populations (Reker et al., 2019; Garvey et al., 2026).
Monitoring Considerations
Clinicians should instruct patients to monitor carefully for both immediate and delayed reactions throughout the protocol. Importantly, mast cell and neuroimmune reactions may present predominantly through autonomic or vascular manifestations rather than classic allergic findings alone (Doherty et al., 2018; El-Rhermoul et al., 2023).
Patients should monitor for:
• Hypotension or relative blood pressure drops
• Presyncope, dizziness, or weakness
• New or worsening tachycardia
• Cognitive or neurologic symptoms
• Delayed fatigue or post-exertional worsening
• Gastrointestinal distress or inflammatory amplification
Importantly, hypotension without cutaneous symptoms may still represent clinically significant mast cell mediated reactions and should not be dismissed solely because visible swelling or urticaria are absent. Current anaphylaxis literature increasingly recognizes that serious systemic reactions may occur without classic dermatologic findings, particularly in mast cell-associated disorders and complex hypersensitivity states (Cardona et al., 2020; Golden et al., 2024).
Observation windows are intentionally extended because delayed worsening appears common in highly reactive neuroimmune populations. Emerging literature in ME/CFS and Long COVID increasingly supports the existence of delayed physiologic deterioration involving autonomic dysfunction, inflammatory amplification, impaired energy metabolism, and post-exertional symptom exacerbation rather than purely immediate hypersensitivity mechanisms (Komaroff and Lipkin, 2021; Wirth and Scheibenbogen, 2023).
Emergency Preparedness
Where clinically appropriate, providers may pre-authorize:
• Antihistamine stacking within defined limits
• Short term corticosteroid escalation
• Hydration support strategies
• Use of epinephrine according to existing anaphylaxis plans
Patients should also be counseled regarding:
• Early signs of severe reaction
• When to discontinue escalation
• When urgent or emergent care is appropriate
• Delayed escalation phenomena following apparently tolerated exposures
This precautionary approach reflects increasing recognition that mast cell and neuroimmune reactions may evolve over hours rather than minutes and may present through cardiovascular, autonomic, neurologic, or inflammatory manifestations rather than classic IgE-mediated allergy patterns alone (Shaker et al., 2020; Cardona et al., 2020).
Clinical Applications in MCAS, Long COVID, ME/CFS, and POTS
The Body First Trial Protocol™ may have applications extending beyond individual patient use alone. High reactivity patients frequently experience treatment abandonment, repeated emergency department utilization, fragmented care, and loss of clinician trust after failed medication initiation attempts. Conservative sequential exposure frameworks may therefore help preserve access to clinically necessary therapies while reducing avoidable destabilization events.
The protocol may be particularly useful:
• In outpatient settings to reduce avoidable ER utilization
• During scheduled clinic visits for supervised first-dose trials
• When specialty care access is limited or delayed
• In patients with prior medication intolerance despite clinical necessity
• In compounding pharmacy collaborations involving excipient sensitivity
• In remote monitoring and future AI assisted tolerability systems
Within the CYNAERA systems framework, tolerability is interpreted as a dynamic systems phenomenon rather than a fixed binary property of a medication or substance. A patient may tolerate a therapy during periods of relative biologic stability yet fail the same intervention during post-exertional deterioration, wildfire smoke exposure, mold exposure, sleep disruption, viral reactivation, menstrual fluctuation, or autonomic amplification. This interpretation aligns with emerging literature describing fluctuating physiologic reserve and multisystem instability across post-viral and mast cell associated chronic illness populations (Sumantri and Rengganis, 2023; Rohrhofer et al., 2025).
Conclusion
The Body First Trial Protocol™ offers a structured, conservative framework for medication and substance initiation in patients with complex immunologic, autonomic, and neuroimmune sensitivity. By prioritizing physiologic signaling over conventional dosing timelines, the protocol provides a safer entry pathway for therapies that might otherwise become inaccessible to highly reactive patients.
More broadly, the framework proposes a reframing of treatment intolerance itself. Rather than viewing tolerance as a fixed binary property, the protocol interprets tolerability as a dynamic interaction between exposure burden and current physiologic reserve. This interpretation is supported by growing literature describing fluctuating autonomic stability, mast cell activation, neuroimmune dysfunction, and impaired adaptive capacity across Long COVID, ME/CFS, dysautonomia, and related post-infectious chronic illnesses (Doherty et al., 2018; El-Rhermoul et al., 2023; Rohrhofer et al., 2025; Wirth and Scheibenbogen, 2023).
The Body First Trial Protocol™ extends the broader STAIR Stable Method™ philosophy into practical substance initiation and tolerability sequencing for highly reactive patients. By prioritizing stabilization, timing, exposure burden, and physiologic readiness before escalation, the protocol reframes treatment intolerance as a dynamic systems phenomenon rather than a fixed binary characteristic of the patient or substance itself.
Frequently Asked Questions
Is The Body-First Trial Protocol™ only for MCAS patients?
No. Although the protocol was developed with mast cell-sensitive populations in mind, it may also be relevant for patients with Long COVID, ME/CFS, POTS, dysautonomia, multiple chemical sensitivity, post-infectious autoimmune overlap, and other neuroimmune conditions involving medication intolerance or physiologic instability. The framework focuses on state-dependent tolerability rather than a single diagnosis.
Does reacting to medications automatically mean someone has MCAS?
No. Medication sensitivity alone is not sufficient to diagnose MCAS. The protocol is intended as a conservative safety and exposure-sequencing framework, not a standalone diagnostic tool. Medication intolerance may involve mast cell activation, autonomic dysfunction, excipient sensitivity, inflammatory amplification, impaired detoxification capacity, environmental exposure burden, or overlapping physiologic mechanisms.
Why do some patients tolerate a substance later after previously reacting to it?
The protocol is based on the principle that tolerability may be state-dependent rather than fixed. Some patients appear capable of tolerating the same intervention once inflammatory load, autonomic instability, mast cell activation, environmental exposure, or physiologic stress have been reduced. Within the STAIR Stable Method™, readiness is interpreted as a systems-level biologic state rather than a static characteristic of the patient or therapy.
Why does the protocol begin with skin and mucosal exposure rather than oral dosing?
Highly reactive patients may experience disproportionate responses to rapid systemic exposure. Sequential barrier-to-systemic exposure allows lower-risk assessment before introducing full gastrointestinal absorption and systemic exposure burden. This approach may help reduce destabilization risk in sensitive populations.
Why are environmental triggers included in a medication tolerance protocol?
Many highly reactive patients focus primarily on foods or medications while overlooking inhaled environmental triggers such as mold, wildfire smoke, fragrances, cleaning chemicals, volatile organic compounds, or off-gassing materials. Ongoing environmental exposure may elevate baseline inflammatory activation and reduce treatment tolerability thresholds.
Why does the protocol recommend delaying trials during flares or post-exertional worsening?
Increasing evidence suggests that autonomic instability, inflammatory amplification, immune activation, and post-exertional symptom worsening may alter physiologic reserve and medication tolerance in post-viral and mast cell-associated chronic illnesses. Introducing new exposures during periods of instability may increase risk of disproportionate reactions.
Is this protocol anti-medication?
No. The protocol is specifically intended to preserve therapeutic access for patients who might otherwise abandon treatment entirely after repeated destabilizing reactions. The framework does not discourage treatment. It proposes that stabilization, sequencing, and physiologic readiness may influence whether treatment becomes tolerable.
Can this protocol be used in clinical settings?
Yes. The framework may be adaptable to outpatient clinics, Long COVID programs, dysautonomia centers, mast cell specialty clinics, compounding pharmacy collaborations, remote monitoring systems, and supervised first-dose trials. Some patients may also benefit from initiating trials during scheduled clinical appointments rather than alone at home.
Why are some reactions delayed by hours or days?
Not all hypersensitivity reactions are immediate IgE-mediated events. Patients with MCAS, ME/CFS, Long COVID, and autonomic dysfunction may experience delayed inflammatory amplification, autonomic worsening, mast cell mediator accumulation, post-exertional symptom escalation, or neuroimmune destabilization hours after exposure.
What makes The Body-First Trial Protocol™ different from “start low and go slow”?
Traditional low-dose approaches still assume that systemic exposure begins immediately. The Body-First Trial Protocol™ instead utilizes sequential barrier-to-systemic exposure progression, beginning with external exposure before advancing to mucosal and diluted systemic administration. The framework also incorporates environmental load, autonomic state, inflammatory timing, and physiologic readiness into tolerability assessment.
Appendix A
MCAS Flag™ Super Sensitive Screening Checklist
Purpose
The MCAS Flag™ Super-Sensitive Screening Checklist is a preliminary triage framework designed to identify patients who may have underrecognized mast cell activation patterns despite inconclusive standard allergy testing or routine laboratory findings. The checklist is intended for use in populations with overlapping neuroimmune and autonomic dysfunction, particularly Long COVID, ME/CFS, POTS, dysautonomia, multiple chemical sensitivity, and related infection associated chronic conditions (Afrin, 2016; Valent et al., 2012; Sumantri and Rengganis, 2023).
This screening tool is not intended to function as a standalone diagnostic instrument. Rather, it is designed to identify patients who may benefit from mast cell informed evaluation, conservative exposure sequencing, environmental assessment, and clinician-supervised stabilization strategies.
Criterion | Description | Score |
Medication Sensitivity | Reacts to unusually low doses of medications or supplements with flushing, dizziness, palpitations, fatigue, rash, tachycardia, or other disproportionate symptoms | 1 |
Lifetime Allergy Profile | Longstanding history of food, environmental, dust, pollen, fragrance, or medication sensitivity, formally diagnosed or self-reported | 1 |
Family Allergy Cluster | Multiple relatives with asthma, eczema, allergic disease, unexplained anaphylaxis, medication sensitivity, or mast cell-related symptoms | 1 |
Post-Infectious Symptom Shift | New or worsening allergies, food intolerance, chemical sensitivity, rashes, or inflammatory reactivity following COVID-19 or another infection | 1 |
Comorbid POTS / ME/CFS / Long COVID | Presence of PEM, orthostatic intolerance, dysautonomia, chronic fatigue, tachycardia, or post-viral illness patterns | 1 |
Environmental Reactivity | Flares triggered by perfumes, smoke, mold, cleaning products, wildfire smoke, off-gassing, or volatile organic compounds | 1 |
Gastrointestinal Trigger Pattern | IBS-like symptoms, nausea, bloating, diarrhea, reflux, or food-triggered inflammatory worsening | 1 |
Scoring Interpretation
Total Score | Interpretation |
0–2 | Lower likelihood of clinically significant mast cell-sensitive phenotype. Continue monitoring if symptoms evolve. |
3–4 | Possible mast cell involvement. Consider mast cell-informed evaluation, environmental trigger review, and cautious medication introduction strategies. |
5–7 | High-likelihood mast cell-reactive phenotype. Consider conservative exposure sequencing, excipient review, environmental remediation assessment, rescue planning, and mast cell-directed interventions under clinician guidance. |
Major Red Flag Indicator
Patients who report that they “react to nearly everything” or describe themselves as “the kind of person who always has weird reactions” should not automatically be dismissed as anxious, medication avoidant, or noncompliant. Within this framework, these descriptions should instead prompt consideration of mast cell sensitive physiology, autonomic instability, excipient intolerance, environmental exposure burden, and impaired adaptive reserve.
Environmental Trigger Consideration
Environmental amplification should be considered in patients with elevated MCAS Flag™ scores. Mold exposure, wildfire smoke, fragrances, volatile organic compounds, cleaning products, off-gassing furniture, and poor indoor air quality may contribute to inflammatory amplification and medication intolerance in highly reactive patients (Wirth and Scheibenbogen, 2023; Rohrhofer et al., 2025). A temporary reduction in symptoms while using a properly fitted N95 respirator over one to two days may suggest an environmental contribution to symptom burden. This observation should not be interpreted as a definitive diagnostic test, but may support further environmental assessment and exposure reduction strategies.
Appendix B
Body-First Trial Protocol™ Quick-Reference Clinical Workflow
Preconditions for Initiation
The protocol should not be initiated under the following conditions:
• Active flare state
• Recent anaphylaxis or near-syncope
• Acute infection or suspected viral reactivation
• Recent major environmental exposure, including mold or wildfire smoke
• Significant psychosocial or physiologic stressor
• Perimenstrual window in patients with known hormone-linked reactivity
Prior to initiation, clinicians are encouraged to:
• Review prior adverse drug reactions
• Establish baseline blood pressure and heart rate when clinically appropriate
• Pre-authorize emergency medication escalation plans when appropriate
• Ensure access to rescue medications and emergency support
Sequential Exposure Framework
Step 1: Cutaneous Contact Test (Day 1)
A minimal quantity of the substance is diluted and applied to intact skin, typically the volar forearm. Patients are observed over a 24-hour period for delayed local or systemic symptoms.
Monitor for:
• Local erythema, pruritus, or flushing
• Fatigue, malaise, dizziness, or cognitive changes
• Tachycardia or autonomic symptoms
• Delayed inflammatory worsening
Step 2: Repeated Cutaneous Exposure (Day 2)
Following gentle removal of residual material, the same diluted exposure is repeated to assess reproducibility or delayed sensitization effects.
Observation period: minimum 24 hours.
Progression requires absence of clinically significant reaction.
Step 3: Oral Mucosal Micro-Exposure (Day 3)
A highly diluted oral solution is prepared. A minimal volume is applied to the oral mucosa without swallowing.
Observation period: minimum 24 hours.
This step assesses mucosal tolerance while limiting systemic gastrointestinal absorption.
Step 4: Diluted Oral Micro-Dose (Day 4+)
If mucosal exposure is tolerated, a diluted oral dose equivalent to approximately one-tenth of the target dose is administered slowly over one to two hours. Premedication with a previously tolerated H1 antihistamine may be considered at clinician discretion.
Observation period: minimum 24 hours.
Step 5: Incremental Oral Dose Escalation (Day 6+)
Dose escalation proceeds gradually every 24 to 48 hours only if prior exposures are tolerated.
Suggested progression:
1/8 dose → 1/4 dose → 1/2 dose → full dose
Escalation speed should be individualized according to prior reaction history and physiologic stability.
Step 6: Standard Formulation Transition (Day 9+)
Once the target dose is tolerated in diluted form, transition to standard intact formulation begins conservatively using fractional dosing. Progression occurs only with sustained tolerance.
Consider excipient sensitivity if diluted formulations are tolerated but intact formulations trigger symptoms.
Monitoring Considerations
Patients should monitor for:
• Hypotension or relative blood pressure drops
• Presyncope, dizziness, or weakness
• New or worsening tachycardia
• Cognitive or neurologic symptoms
• Delayed fatigue or post-exertional worsening
• Gastrointestinal distress or inflammatory amplification
Importantly, hypotension without visible swelling or urticaria may still represent clinically significant mast cell-mediated reactions in highly reactive patients (Cardona et al., 2020; Golden et al., 2024).
Observation windows are intentionally extended because delayed worsening patterns are common in mast cell and neuroimmune populations.
Emergency Preparedness
Where clinically appropriate, providers may pre-authorize:
• Antihistamine stacking within defined limits
• Short-term corticosteroid escalation
• Hydration support strategies
• Use of epinephrine according to existing anaphylaxis plans
Patients should also be counseled regarding:
• Early signs of severe reaction
• When to discontinue escalation
• When urgent or emergent care is appropriate
• Delayed escalation phenomena following apparently tolerated exposures
Appendix C
Patient Home Trial Safety and Stabilization Checklist™
Purpose
The Patient Home Trial Safety and Stabilization Checklist™ was developed to help highly reactive patients reduce destabilization risk when introducing new medications, supplements, foods, beverages, or environmental exposures outside of hospital settings. The checklist is intended to support safer home-based implementation of the Body First Trial Protocol™ in patients with mast cell activation, autonomic dysfunction, neuroimmune sensitivity, post-viral illness, or complex multisystem chronic disease.
This framework recognizes that many patients initiating new therapies do so without immediate specialist access and often after prior experiences of medication intolerance, emergency destabilization, or medical dismissal. The checklist therefore prioritizes environmental stability, rescue preparedness, physiologic timing, and reaction documentation before escalation occurs.
Phase 1: Pre-Trial Stability Assessment
Before introducing a new substance, assess whether your body is currently in a relatively stable physiologic state.
Delay trialing if any of the following are present:
• Active flare or inflammatory worsening
• Recent anaphylaxis, near-syncope, or unexplained collapse
• Acute infection or suspected viral reactivation
• Severe post-exertional malaise or PEM crash state
• Significant sleep deprivation or autonomic instability
• Recent mold exposure, wildfire smoke exposure, or major air-quality change
• Major psychosocial stressor or physiologic stress event
• Menstrual or hormone-linked flare window if applicable
• Significant dehydration, heat exposure, or prolonged exertion
Within the Body First framework, treatment tolerance is interpreted as state-dependent. A therapy that fails during physiologic destabilization may still become tolerable during periods of improved autonomic and inflammatory stability.
Phase 2: Environment and Exposure Control
Before trialing a new substance, evaluate the immediate environment for potential amplification triggers.
Whenever possible:
• Reduce exposure to fragrances, smoke, cleaning chemicals, and aerosols
• Avoid trialing near recent painting, construction, or new furniture off-gassing
• Limit exposure to mold-prone environments or visible water damage
• Avoid simultaneous dietary experimentation during medication trials
• Minimize sensory overload, overheating, and excessive exertion during trial days
Patients with severe environmental sensitivity may benefit from temporary use of a properly fitted N95 respirator during symptom evaluation periods to help determine whether airborne environmental triggers are contributing to baseline instability. Environmental amplification may significantly alter tolerability thresholds in mast cell and neuroimmune populations.
Phase 3: Rescue and Emergency Readiness
Before beginning a trial, ensure rescue planning is already in place.
Patients should confirm access to:
• Previously tolerated antihistamines
• Rescue medications approved by their clinician
• Mast cell stabilizers if prescribed
• Hydration support supplies
• Epinephrine autoinjectors if part of existing emergency plans
• Emergency contact information
• Transportation access if urgent care becomes necessary
Whenever possible, discuss escalation thresholds with a clinician before trialing. Some patients may already have pre-authorized medication escalation plans involving antihistamine stacking, hydration strategies, or short-term corticosteroid adjustments. The goal is to reduce avoidable emergency escalation while preserving patient safety.
Phase 4: Safe Trialing Practices
When initiating a new medication, supplement, food, or beverage:
• Trial only one new substance at a time
• Begin during daylight hours whenever possible
• Avoid initiating immediately before sleep
• Start at the lowest planned exposure level
• Increase slowly and conservatively
• Extend observation periods if delayed worsening commonly occurs
• Do not escalate during active symptom worsening
• Pause escalation after major environmental or physiologic stressors
Patients with histories of severe reactions may benefit from performing first dose trials during scheduled clinic visits or while physically near medical support. Importantly, highly reactive patients often experience delayed worsening patterns rather than immediate reactions alone. A trial should therefore be evaluated not only by immediate tolerance, but also by symptom patterns over the following 24–72 hours.
Phase 5: Reaction Documentation
Patients are encouraged to maintain structured reaction logs throughout the protocol.
Document:
• Date and time of exposure
• Substance name and formulation
• Dose and exposure method
• Premedications used
• Environmental conditions
• Air quality or mold exposure if relevant
• Menstrual phase if applicable
• Heart rate and blood pressure if available
• Immediate symptoms
• Delayed symptoms
• Recovery duration
• Factors that improved or worsened symptoms
Structured documentation may help identify delayed inflammatory patterns, autonomic triggers, excipient sensitivity, environmental amplification, or dose threshold relationships over time.
Phase 6: Stop Criteria
Escalation should be paused or discontinued if patients experience:
• Significant hypotension or presyncope
• Severe tachycardia or chest symptoms
• Progressive neurologic symptoms
• Respiratory compromise
• Severe gastrointestinal escalation
• Delayed crash or PEM-like worsening
• Rapid inflammatory amplification
• Symptoms suggestive of systemic mast cell activation
Importantly, absence of visible swelling or hives does not exclude clinically significant mast cell-mediated reactions. In highly reactive neuroimmune populations, cardiovascular, autonomic, neurologic, and inflammatory symptoms may predominate over classic dermatologic findings (Cardona et al., 2020; Golden et al., 2024).
Final Patient Guidance
The Body First Trial Protocol™ does not assume that patients are fragile. It assumes that physiologic thresholds matter. Highly reactive patients are frequently told they are anxious, exaggerating, medication avoidant, or “reacting to everything.” Within this framework, those experiences are interpreted instead as potential signals of altered autonomic buffering capacity, mast cell instability, environmental amplification, or impaired adaptive reserve. The purpose of this protocol is therefore not to discourage treatment, but to preserve access to treatment through slower, safer, and more physiologically informed introduction strategies.
How to Cite This Paper
Adinig, C. (2026).The Body-First Trial Protocol™. CYNAERA. Available at: https://www.cynaera.com/post/body-first
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Afrin, L.B. (2016) Never Bet Against Occam: Mast Cell Activation Disease and the Modern Epidemics of Chronic Illness and Medical Complexity. Sisters Media.
Akin, C., Valent, P. and Metcalfe, D.D. (2010) ‘Mast cell activation syndrome: proposed diagnostic criteria’, Journal of Allergy and Clinical Immunology, 126(6), pp. 1099–1104.
Caballero, M.L. et al. (2021) ‘Hidden dangers: recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions’, Journal of Allergy and Clinical Immunology: In Practice, 9(8), pp. 2968–2982.
Cardona, V. et al. (2020) ‘World Allergy Organization anaphylaxis guidance 2020’, World Allergy Organization Journal, 13(10), 100472.
Doherty, T.A. et al. (2018) ‘Postural orthostatic tachycardia syndrome and the potential role of mast cell activation’, Autonomic Neuroscience, 215, pp. 83–88.
El-Rhermoul, F.Z. et al. (2023) ‘Autoimmunity in Long COVID and POTS’, Oxford Open Immunology, 4(1), iqad002.
Food and Drug Administration (2023) Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making. Silver Spring, MD: U.S. Food and Drug Administration.
Garvey, L.H. et al. (2026) ‘Hypersensitivity to excipients in drugs: an EAACI position paper’, Allergy. doi: 10.1111/all.70324.
Golden, D.B.K. et al. (2024) ‘Anaphylaxis: A 2023 practice parameter update’, Annals of Allergy, Asthma & Immunology, 132(2), pp. 124–176.
Komaroff, A.L. and Lipkin, W.I. (2021) ‘Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome’, Trends in Molecular Medicine, 27(9), pp. 895–906.
Molderings, G.J. et al. (2011) ‘Pharmacological treatment options for mast cell activation disease’, Naunyn-Schmiedeberg’s Archives of Pharmacology, 383, pp. 423–435.
NIH RECOVER Initiative (2024) Reviewing RECOVER’s Impact in 2024. Researching COVID to Enhance Recovery.
Reker, D. et al. (2019) ‘Inactive ingredients in oral medications’, Science Translational Medicine, 11(483), eaau6753.
Rohrhofer, J. et al. (2025) ‘The clinical relevance of mast cell activation in myalgic encephalomyelitis/chronic fatigue syndrome’, Diagnostics, 15(22), 2828.
Shaker, M.S. et al. (2020) ‘Anaphylaxis: A 2020 practice parameter update, systematic review, and GRADE analysis’, Journal of Allergy and Clinical Immunology, 145(4), pp. 1082–1123.
Sumantri, S. and Rengganis, I. (2023) ‘Immunological dysfunction and mast cell activation syndrome in long COVID’, Asia Pacific Allergy, 13(1), pp. 50–53.
Theoharides, T.C., Valent, P. and Akin, C. (2015) ‘Mast cells, mastocytosis, and related disorders’, New England Journal of Medicine, 373(2), pp. 163–172.
Valent, P. et al. (2012) ‘Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes’, International Archives of Allergy and Immunology, 157(3), pp. 215–225.
Wirth, K. and Scheibenbogen, C. (2020) ‘A unifying hypothesis of the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome: recognitions from the finding of autoantibodies against β2-adrenergic receptors’, Autoimmunity Reviews, 19(6), 102527.
Comments